LiveSMART Trial to Prevent Falls in Patients with Cirrhosis

Description

This multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver transplant over 24 weeks. Participants that are enrolled will be randomized to stage one of this project for approximately 12 weeks. After completing stage one, participants will be re-randomized to stage 2 of the project that will last approximately 12 more weeks. The study hypothesizes that sequential lactulose/TeleTai-Chi will reduce falls, incident overt HE, death and physical frailty and will improve cognitive function, and Health Related Quality of Life (HRQOL) over 24 weeks compared to other treatment combinations.

Conditions

Cirrhosis, Liver, Portal Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

This multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver transplant over 24 weeks. Participants that are enrolled will be randomized to stage one of this project for approximately 12 weeks. After completing stage one, participants will be re-randomized to stage 2 of the project that will last approximately 12 more weeks. The study hypothesizes that sequential lactulose/TeleTai-Chi will reduce falls, incident overt HE, death and physical frailty and will improve cognitive function, and Health Related Quality of Life (HRQOL) over 24 weeks compared to other treatment combinations.

LiveSMART: a Sequential, Multiple Assignment Randomized Trial to Prevent Falls in Patients with Cirrhosis

LiveSMART Trial to Prevent Falls in Patients with Cirrhosis

Condition
Cirrhosis, Liver
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Dallas

Baylor Scott & White Research Institute (BSW), Dallas, Texas, United States, 75246

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Clinical diagnosis of cirrhosis based on histology and/or imaging specified in the protocol.
  • * Evidence of portal hypertension - must meet at least one of the following criteria:
  • * Ascites (present or within past 2 years)
  • * Varices (seen by Esophagogastroduodenoscopy or by Ultrasound(US) or cross-sectional imaging)
  • * Fibroscan Liver stiffness measurement (LSM) \>25 kilopascals (kPa) (if no other factors present)
  • * Magnetic resonance elastography (MRE) LSM \> 5 kPa (if no other factors present)
  • * Acoustic radiation force impulse LSM \> 17kpa (if no other factors present)
  • * Hepatic vein pressure gradient \> 10 millimetres of mercury (mmHg)
  • * Portal hypertensive gastropathy seen on Esophagogastroduodenoscopy
  • * Platelet count \< 80/ units per liter (uL)
  • * Recanalized umbilical vein (by US or cross-sectional imaging)
  • * Access to Wireless Fidelity (Wi-Fi) at home
  • * Owns or access to a smartphone, tablet or computer
  • * English or Spanish speaking
  • * Willing to participate in exercise program
  • * Overt hepatic encephalopathy (HE) within 6 months, requiring \>28 days total of lactulose
  • * Took lactulose for non - HE reasons for \>28 days total in last 6 months
  • * Took Rifaximin for \> 28 days total in last 6 months
  • * Model for End Stage Liver Disease (MELD) \> 25 (Exception: MELD \> 25 with clinically stable End-Stage Renal Disease (ESRD) for whom the bilirubin is \< 5 g/dL)
  • * Barcelona Clinic Liver Cancer (BCLC) \> C Hepatocellular Carcinoma (HCC)
  • * Currently taking Sorafenib, Atezolizumab/Bevacizumab, Regorafinib, or Cabozatinib
  • * Greater than (\>) 3 paracentesis/month in last 2 months
  • * Active Metastatic solid malignancy or acute leukemia within last 3 years
  • * Severe cognitive, vision, or hearing impairment (without use of corrective lenses or hearing assist devices) or psychiatric illness precluding study participation
  • * Currently participates in Tai-Chi or performs \>150 min/week vigorous physical activity
  • * Currently receiving lower body physical and/or occupational therapy
  • * Living in an assisted living facility
  • * Hemoglobin A1C \> 12 (within past 12 months)
  • * Requires a low galactose diet
  • * Deemed unsuitable by the study investigator
  • * Adult \> 18 years of age
  • * Informal caregiver of a participant enrolled in LIVE-SMART
  • * English speaking

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

Elliott Tapper, MD, PRINCIPAL_INVESTIGATOR, University of Michigan

Marina Serper, MD, MS, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2025-09